CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
Fimasartan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02704702
NCT02704702Phase 1Completed
CompareCT.gov

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

Boryung Pharmaceutical Co., Ltd·interventional·Posted Mar 10, 2016·Updated Nov 2, 2018

In Brief

A Phase 1 clinical trial evaluating Fimasartan, Rosuvastatin, and 1 other intervention for Hypertension. Completed, enrolled 36 participants.

Detailed Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and rosuvastatin when coadministered or administered alone as a single dose or as multiple doses to healthy male subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 10, 2016
Enrollment StartMar 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.3 years ago

Interventions

Fimasartandrug

Rosuvastatindrug

Fimasartan + Rosuvastatindrug